Diabetes Therapy
Pravastatin reduces cardiovascular event rates in diabetes, chronic kidney disease
Published in Obesity and Diabetes Week, February 6th, 2006
"Although diabetes is a major cause of chronic kidney disease (CKD), limited data describe the cardiovascular benefit of hydroxymethyl glutaryl CoA reductase inhibitors (statins) in people with both of these conditions. This study sought to determine whether pravastatin reduced the incidence of first or recurrent cardiovascular events in people with nondialysis-dependent CKD and concomitant diabetes, using data from three randomized trials of pravastatin 40 mg daily versus placebo," researchers in Canada report.
M. Tonelli and colleagues at the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Bariatric Surgery
Obesity surgery on the rise, especially among youth - Diabetes Research
Peptidomics is developed to screen for biomarkers in mouse models of obesity and diabetes - Obesity Pathogenesis
Mu-opioid receptor-deficient mice demonstrate resistance to diet-induced obesity - Obesity Pathogenesis
Watching television is an important factor in predicting childhood obesity - Obesity Research
U.S. NIH releases statement on its commitment to obesity and diabetes research - Adverse Drug Reaction
Sulfonylurea drugs associated with higher mortality rate in diabetes patients - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
